

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/599,839	Applicant: Marc Chapdelaine, et al.
371 Filing Date: October 12, 2006	Attorney Docket No.: 101430-1P US
Examiner: Not Known	Group Art Unit : 1614
Customer No.: 22466	Confirmation No.: 5371
Title: Novel 2-(1-aza-bicyclo[2.2.2]oct-3-yl) . . . Nicotinic Acetylcholine Receptor	

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir,

Applicants submit herewith a list of patents and publications pursuant to the duty to disclose in accordance with 37 C.F.R. § 1.56.

In accordance with 37 C.F.R. § 1.97 (g) and (h), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made or that the information cited is material to patentability as defined in 37 C.F.R. § 1.56.

In accordance with the U.S. Patent Office's partial waiver of the requirement under 37 C.F.R. 1.98(a)(2)(i), only copies of the foreign patent documents and non-patent publications are enclosed.

REMARKS

In accordance with the provisions of 37 C.F.R. 1.97, this statement is being filed within three (3) months of the **filling date** of a national application other than a continued prosecution application under 37 C.F.R. 1.53(d), or within three (3) months of the **date of entry of the national stage** as set forth in 37 C.F.R. 1.491 in an international application, or before the mailing of the **first Office Action** on the merits, or before the mailing of a **first Office Action** after the filing of a request for continued examination under 37 C.F.R. 1.114.

It is respectfully requested that each of the patents and publications listed on the attached Form SB08, and other information contained herein, be considered by the Examiner and made of record in this application

Although Applicants believe no fees are due, the Commissioner is hereby authorized to charge any deficiency in the fees or credit any overpayment to deposit account No. 260166, referencing Attorney Docket No. 101430-1P US.

Respectfully submitted,



Name: Kenneth F. Mitchell
Dated:

Reg. No.: 42.007
Phone No.: 302.886.7466
Global Intellectual Property, Patents,
AstraZeneca,
1800 Concord Pike,
Wilmington,
DE-19850-5437

Enclosures: Form SB08A